Search Results
Center for Oncological Research, University of Antwerp, Antwerp, Belgium
Search for other papers by Matthias Beyens in
Google Scholar
PubMed
Center for Oncological Research, University of Antwerp, Antwerp, Belgium
Section of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
Search for other papers by Timon Vandamme in
Google Scholar
PubMed
Search for other papers by Marc Peeters in
Google Scholar
PubMed
Center for Oncological Research, University of Antwerp, Antwerp, Belgium
Search for other papers by Guy Van Camp in
Google Scholar
PubMed
Center for Oncological Research, University of Antwerp, Antwerp, Belgium
Search for other papers by Ken Op de Beeck in
Google Scholar
PubMed
regulating cell growth, proliferation, survival and protein synthesis in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ( Missiaglia et al. 2010 , Jiao et al. 2011 , Kasajima et al. 2011 ). GEP-NETs include small intestinal NETs (siNETs) and
Search for other papers by Ulrich-Frank Pape in
Google Scholar
PubMed
Search for other papers by Uta Berndt in
Google Scholar
PubMed
Search for other papers by Jacqueline Müller-Nordhorn in
Google Scholar
PubMed
Department of Hepatology and Gastroenterology, Institute for Social Medicine, Institute for Pathology, Department of Gastroenterology, Charité, Campus Virchow Klinikum
Search for other papers by Michael Böhmig in
Google Scholar
PubMed
Search for other papers by Stephanie Roll in
Google Scholar
PubMed
Search for other papers by Martin Koch in
Google Scholar
PubMed
Search for other papers by Stefan N Willich in
Google Scholar
PubMed
Search for other papers by Bertram Wiedenmann in
Google Scholar
PubMed
. 2004 ). According to the largest series of NET studied to date ( Modlin et al . 2003 ), the majority of NET arise within the gastroenteropancreatic system (GEP) while the bronchial tract represents the second most frequent primary tumour localization
Search for other papers by Dik J Kwekkeboom in
Google Scholar
PubMed
Search for other papers by Boen L Kam in
Google Scholar
PubMed
Search for other papers by Martijn van Essen in
Google Scholar
PubMed
Search for other papers by Jaap J M Teunissen in
Google Scholar
PubMed
Search for other papers by Casper H J van Eijck in
Google Scholar
PubMed
Search for other papers by Roelf Valkema in
Google Scholar
PubMed
Search for other papers by Marion de Jong in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Eric P Krenning in
Google Scholar
PubMed
) Astrocytoma ( Schmidt et al . 1998 ) High sensitivity, detection rate >75%; intermediate sensitivity, detection rate 40–75%. Sensitivity is either patient or lesion based. GEPNET, gastroenteropancreatic neuroendocrine tumor; NHL, non-Hodgkin lymphoma
Search for other papers by A Mohamed in
Google Scholar
PubMed
Search for other papers by M Trybula in
Google Scholar
PubMed
Search for other papers by S L Asa in
Google Scholar
PubMed
Search for other papers by T R Halfdanarson in
Google Scholar
PubMed
Search for other papers by M B Sonbol in
Google Scholar
PubMed
Introduction Although rare, gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have seen a significant increase in annual incidence over recent decades ( Fraenkel et al. 2014 , Dasari et al. 2017 , Das & Dasari 2021 , White et
Search for other papers by Wiebke Werner in
Google Scholar
PubMed
Search for other papers by Katharina Detjen in
Google Scholar
PubMed
Search for other papers by Alix Bruneau in
Google Scholar
PubMed
Search for other papers by Isabella Lurje in
Google Scholar
PubMed
Search for other papers by Natalie Nestel in
Google Scholar
PubMed
Search for other papers by Henning Jann in
Google Scholar
PubMed
Search for other papers by Frank Tacke in
Google Scholar
PubMed
Search for other papers by Bertram Wiedenmann in
Google Scholar
PubMed
Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine, University Düsseldorf, Düsseldorf, Germany
Search for other papers by Christoph Roderburg in
Google Scholar
PubMed
Search for other papers by Linda Hammerich in
Google Scholar
PubMed
Introduction Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) account for approximately two-thirds of all neuroendocrine malignancies ( Kaliszewski et al. 2022 ). The current World Health Organization (WHO) classification system
Department of Biomedical Sciences, Cluster for Molecular Imaging, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Esben Andreas Carlsen in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Search for other papers by Dan Granberg in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
Search for other papers by Hojjat Ahmadzadehfar in
Google Scholar
PubMed
Search for other papers by Chiara Maria Grana in
Google Scholar
PubMed
Search for other papers by Wouter T Zandee in
Google Scholar
PubMed
Search for other papers by Jaroslaw Cwikla in
Google Scholar
PubMed
Search for other papers by Martin A Walter in
Google Scholar
PubMed
Search for other papers by Peter Sandor Oturai in
Google Scholar
PubMed
Search for other papers by Anja Rinke in
Google Scholar
PubMed
Search for other papers by Andrew Weaver in
Google Scholar
PubMed
Search for other papers by Andrea Frilling in
Google Scholar
PubMed
Search for other papers by Sara Gritti in
Google Scholar
PubMed
Search for other papers by Anne Kirstine Arveschoug in
Google Scholar
PubMed
Search for other papers by Amichay Meirovitz in
Google Scholar
PubMed
Departments of Surgical Gastroenterology and Clinical Endocrinology, Rigshospitalet, Copenhagen, Denmark
Search for other papers by Ulrich Knigge in
Google Scholar
PubMed
Department of Clinical Science, University of Bergen, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
poorly differentiated high-grade neuroendocrine carcinomas (G3). The terminology of NEN G3 relates to all high-grade (G3, Ki-67 >20%) neuroendocrine malignancies; i.e. both NET G3 and NEC. Gastroenteropancreatic (GEP) NENs G3 are rare, highly malignant
Search for other papers by M Fraenkel in
Google Scholar
PubMed
Search for other papers by M Kim in
Google Scholar
PubMed
Endocrinology, Mount Sinai Medical Center, Department of Clinical Medicine and Surgery, Endocrinology, Erasmus MC, Department of Internal Medicine, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheeba, Israel
Search for other papers by A Faggiano in
Google Scholar
PubMed
Search for other papers by W W de Herder in
Google Scholar
PubMed
Search for other papers by G D Valk in
Google Scholar
PubMed
Search for other papers by On behalf of the Knowledge NETwork in
Google Scholar
PubMed
studies being published, we still lack adequate epidemiological information on NETs. This lack of data only partially explains the strong discrepancy between the estimated incidence of gastroenteropancreatic (GEP)-NETs and the higher frequency of these
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Andreas Venizelos in
Google Scholar
PubMed
Department of Clinical Science, University of Bergen, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
Search for other papers by Hege Elvebakken in
Google Scholar
PubMed
Search for other papers by Aurel Perren in
Google Scholar
PubMed
Search for other papers by Inger Marie B Lothe in
Google Scholar
PubMed
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Search for other papers by Geir Olav Hjortland in
Google Scholar
PubMed
Department of Medical Radiation Physics, Lund University, Lund, Sweden
Search for other papers by Anna Sundlöv in
Google Scholar
PubMed
Search for other papers by Johanna Svensson in
Google Scholar
PubMed
Search for other papers by Harrish Garresori in
Google Scholar
PubMed
Search for other papers by Christian Kersten in
Google Scholar
PubMed
Department of Oncology, St. Olavs Hospital, Trondheim, Norway
Search for other papers by Eva Hofsli in
Google Scholar
PubMed
Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Search for other papers by Sönke Detlefsen in
Google Scholar
PubMed
Search for other papers by Lene W Vestermark in
Google Scholar
PubMed
Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
Search for other papers by Morten Ladekarl in
Google Scholar
PubMed
Search for other papers by Elizaveta Mitkina Tabaksblat in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Stian Knappskog in
Google Scholar
PubMed
Introduction Neuroendocrine neoplasms (NENs) constitute ~2% of all malignancies and are frequently located in the gastrointestinal (GI) tract and pancreas. High-grade gastroenteropancreatic (HG-GEP) NENs are among the most aggressive cancers
Search for other papers by Cosimo Durante in
Google Scholar
PubMed
Search for other papers by Houda Boukheris in
Google Scholar
PubMed
Search for other papers by Clarisse Dromain in
Google Scholar
PubMed
Search for other papers by Pierre Duvillard in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Dominique Elias in
Google Scholar
PubMed
Search for other papers by Thierry de Baere in
Google Scholar
PubMed
Search for other papers by David Malka in
Google Scholar
PubMed
Search for other papers by Jean Lumbroso in
Google Scholar
PubMed
Search for other papers by Joël Guigay in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by Michel Ducreux in
Google Scholar
PubMed
Search for other papers by Eric Baudin in
Google Scholar
PubMed
Introduction Gastroenteropancreatic neuroendocrine tumors (GEP NET), recently renamed endocrine tumors, are a group of tumors defined by the expression of a set of structural proteins and hormonal products common to neurons and endocrine cells
Search for other papers by M Heetfeld in
Google Scholar
PubMed
Search for other papers by C N Chougnet in
Google Scholar
PubMed
Search for other papers by I H Olsen in
Google Scholar
PubMed
Search for other papers by A Rinke in
Google Scholar
PubMed
Search for other papers by I Borbath in
Google Scholar
PubMed
Search for other papers by G Crespo in
Google Scholar
PubMed
Search for other papers by J Barriuso in
Google Scholar
PubMed
Search for other papers by M Pavel in
Google Scholar
PubMed
Search for other papers by D O'Toole in
Google Scholar
PubMed
Search for other papers by T Walter in
Google Scholar
PubMed
Search for other papers by other Knowledge Network members in
Google Scholar
PubMed
Introduction Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are rare tumors defined by the presence of specific biomarkers ( Yao et al . 2008 ). The differentiation status is a major prognostic factor, regardless of primary site and